Building on results from the AELIX-002 trial with HIVACAT T-cell immunogen (HTI)-based vaccines, the AELIX-003 (NCT04364035) trial tested the safety of the combination of ChAdOx1.HTI (C) and MVA.HTI (M), with the TLR7 agonist vesatolimod (VES), in a double-blind, placebo-controlled, randomized clinical trial in 50 virally suppressed early-treated men with HIV-1 infection.
View Article and Find Full Text PDFIntroduction: The POET trial demonstrated that moving from intravenous to oral antibiotics in stable patients with left-sided infective endocarditis (IE) was noninferior to fully parenteral treatment. However, it did not compare outpatient strategies.
Methods: The OraPAT-IE GAMES trial is a noninferiority, multicenter, randomized, open-label study aimed to compare partial oral versus outpatient parenteral antibiotic therapy (OPAT) for consolidation of antibiotic treatment in left-sided IE.
The follicular fluid (FF) is crucial for providing oocytes with an ideal environment that promotes their development and maturation. Not only does this fluid supply nutrients and hormones, but also other components that protect both follicular cells and the oocyte itself from potential harmful factors, such as those inducing oxidative stress (OS). The FF has also been suggested to have beneficial effects on sperm when they reach the oviduct.
View Article and Find Full Text PDFAddressing multidrug-resistant microbial infections linked to implantable biomedical devices is an urgent need. In recent years, there has been an active exploration of different surface coatings to prevent and combat drug-resistant microbes. In this research, we present a facile chemical modification of thermoplastic polyurethane (TPU) surfaces with poly(ethylene glycol)-based recombinant human α-defensin 5 (HD5) protein with antimicrobial activity.
View Article and Find Full Text PDFObjective: People with HIV-HCV co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) to cure HCV. ART is typically prioritized, but delays in DAA initiation may increase the risk of liver-related events and HCV transmission to others.
Design: Target trial emulation with observational data collected in routine clinical practice from a collaboration of cohorts from Europe and North America.